Chronic Obstructive Pulmonary Disease with MCC DRG Reimbursement

Summary & Overview

Chronic Obstructive Pulmonary Disease with MCC: Inpatient Reimbursement Overview

DRG 190 addresses hospital stays for acute exacerbations of chronic obstructive pulmonary disease with at least one Major Complication or Comorbidity, encompassing severe respiratory compromise and complex comorbid management. It matters for inpatient reimbursement because the Major Complication or Comorbidity designation raises the case weight and payment level under Medicare rules, aligning payment with higher resource use.

Chronic Obstructive Pulmonary Disease with MCCDRG Chronic Obstructive Pulmonary Disease with MCCDRG 190Diagnosis-Related GroupInpatient ReimbursementMedicarePulmonologyRespiratory TherapyHospital Medicine

DRG 190 Overview

DRG 190 covers inpatient admissions for patients with an acute exacerbation of chronic obstructive pulmonary disease accompanied by at least one Major Complication or Comorbidity. Typical clinical issues include severe respiratory failure, need for intensive respiratory support, or significant comorbid conditions that increase resource use. This Diagnosis-Related Group is important for Medicare payment because the presence of a Major Complication or Comorbidity elevates the relative payment weight, reflecting higher expected costs of care. Accurate coding of the primary diagnosis and all Major Complication or Comorbidity conditions directly affects reimbursement classification.

National Payment Rates

Across payers the observed rate range runs roughly from $370 to $42K, with the widest spread between Anthem and BCBS/other payers as shown in the table and chart below. Private commercial payers vary substantially: Aetna and Cigna cluster around mean levels near $18K, while Anthem shows a higher maximum and wider distribution. Refer to the table and chart below for payer-specific quartiles and medians.

Mean Rates by Payer — National — DRG 190

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska’s DRG 190 mean payments range from 17K to 27K across payers, with Blue Cross Blue Shield at the low end (17K) and Cigna at the high end (27K). The state exhibits a compact distribution with two payers offering identical low means of 17K, while Cigna deviates upward relative to those peers. This pattern is visible in the table and chart below.

Key Insights for Alaska

Anthem is the highest-paying payer in Alaska with a mean of 27K, while BCBS (Blue Cross Blue Shield) and Anthem’s peer Anthem-level payer (Anthem listings at 17K for BCBS/Anthem duplicates) show the lowest consistent mean at 17K — BCBS is the lowest payer at 17K.
Alaska’s payer means range narrowly from 17K to 27K, with Cigna notably above the others (mean 27K) while Blue Cross Blue Shield and BCBS-equivalent payers sit at the low bound; overall means in Alaska sit lower than some national medians, especially compared with national Anthem and Aetna medians around 18K–20K.

Clinical Trials

Acute exacerbation interventional trials assessing short-term therapies to reduce respiratory failure and need for mechanical ventilation: These studies enroll hospitalized COPD patients with severe acute exacerbations and major complications (eg, respiratory failure, sepsis, or heart failure) to evaluate interventions such as noninvasive ventilation strategies, advanced oxygenation protocols, or adjunctive anti-inflammatory approaches delivered during the index admission. Research focuses on immediate clinical endpoints (need for ICU transfer, duration of ventilatory support, in-hospital mortality) and is relevant to providers and payers because reducing resource-intensive care and length of stay directly impacts inpatient costs and DRG reimbursement for this high-acuity group.
Comparative effectiveness studies of inpatient comorbidity management and bundled care pathways: These pragmatic trials compare different models of inpatient care for COPD patients with major comorbid conditions (eg, ischemic heart disease, diabetes, renal dysfunction) to determine which bundles of diagnostics, multidisciplinary management, and medication reconciliation best prevent complications. They typically enroll the heterogeneous population coded to this DRG to evaluate outcomes such as readmission rates, complication incidence, and total hospital cost per episode; findings inform clinicians on care processes that improve outcomes and help payers design value-based payment or quality metrics tailored to complex COPD admissions.
Post-discharge outcomes and transitional care trials targeting recurrent exacerbations and rehospitalization: These studies follow survivors of a COPD admission with MCC to test interventions delivered at discharge or in the early post-discharge period—such as enhanced home monitoring, structured pulmonary rehabilitation referral, or intensive care-coordination—to reduce 30- and 90-day readmissions and downstream utilization. The patient population includes individuals with high comorbidity burden and prior healthcare use; evidence from these trials is crucial for providers and payers to allocate resources to effective transitional care strategies that lower readmission penalties and improve long-term cost-effectiveness for this DRG.

Interstitial Lung Disease without CC/MCC: Inpatient Reimbursement Overview

168-OTHER-RESPIRATORY-SYSTEM-O-R-PROCEDURES-WITHOUT-CC-MCC

Other Respiratory System O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

204-RESPIRATORY-SIGNS-AND-SYMPTOMS

Respiratory Signs and Symptoms: Inpatient Reimbursement Overview

186-PLEURAL-EFFUSION-WITH-MCC

Pleural Effusion with MCC: Inpatient Reimbursement Overview

180-RESPIRATORY-NEOPLASMS-WITH-MCC

Respiratory Neoplasms with MCC: Inpatient Reimbursement Overview

165-MAJOR-CHEST-PROCEDURES-WITHOUT-CC-MCC

Major Chest Procedures without CC/MCC: Inpatient Reimbursement Overview

197-INTERSTITIAL-LUNG-DISEASE-WITH-CC

Interstitial Lung Disease with CC: Inpatient Reimbursement Overview

173-ULTRASOUND-ACCELERATED-AND-OTHER-THROMBOLYSIS-WITH-PRINCIPAL-DIAGNOSIS-PULMONARY-EMBOLISM

Ultrasound Accelerated and Other Thrombolysis with Principal Diagnosis Pulmonary Embolism: Inpatient Reimbursement Overview

202-BRONCHITIS-AND-ASTHMA-WITH-CC-MCC

Bronchitis and Asthma with CC/MCC: Inpatient Reimbursement Overview

191-CHRONIC-OBSTRUCTIVE-PULMONARY-DISEASE-WITH-CC

Chronic Obstructive Pulmonary Disease with CC: Inpatient Reimbursement Overview

Showing 1–10 of 40

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$10K	$48K	$8.1K	59K